Member Info for CR1909

I think only time will tell.

The results aren’t terrible for all the reasons that you and to his credit Andybe (who has had much stick on this board recently) have described.

However, the big disappointment is that we’re still no further forward really in terms of approval and when to give the drug (as far as we know).

Between the P2 and P3 (home and hospital settings) and Activ-2, it still feels like there is something here. Maybe not the complete game changer we all hoped for but something which can help in terms of Covid and preparation for future variants.

The big questions now lie with the directors and how they take the company forward. No doubt there is plenty going on behind the scenes today.

There are no words - just make sure you look after yourselves.

I’m sure there are plenty of others in the same boat and if nothing else sharing this might help them a little. Nobody is alone here, no matter how bad it might seem.

Can someone lend me the bus fare?!

This is the stage I’ve reached HSD and where we need to hear from the leaders at SNG.

The drug has shown some efficacy - just as it did in the home trial and presumably in Activ-2.

Not as great as we hoped, but something.

So where do we go from here? Without statistical significance is there a market for this? Isn’t it better to have this treatment as an option? Are we still going into production? All questions which need answered.

Re-read it now.

36% is encouraging but only for a small number of participants, which is disappointing.

Sorry, Andybe I may have misunderstood the results (probably due to shock).

Are the per protocol cohort then the group we were looking to treat originally eg no other treatments etc?

So, like many I’m a bit conflicted. Do I sell and take the loss, or wait it out and potentially take a bigger loss or maybe a smaller loss.

The trial failed - simple as.

But is there still an opportunity for some stockpiling? The ITT cohort were 17% less likely to proceed to serious Illness or death. Thats even with other treatments.

If another variant comes along and makes some treatments redundant, is it still worthwhile having some SNG001 in the cupboard?!

I don’t think today of all days, is the time to have a go at the MM’s.

Good luck to them if they make a killing, that’s what most of us here were trying to do.

It’ll be interesting to hear the next steps of the company.

And I certainly don’t see it being anytime soon - there wouldn’t be any rush to get this through I wouldn’t think.

If they get some very good sales people in then they might have something to sell. In reality though I don’t think a lot of countries will be looking to spend a lot of money on a treatment which doesn’t have huge benefits so any orders would be small.

I always knew there was a risk here but to show so little sign of improvement in the endpoints is staggering.

Been some journey on this board. Take care everyone and better luck with future investments.

A lot of us are in the same boat. Don’t do anything stupid.

****!!

I don’t think you could call any of the companies who’ve had drugs released to the market ‘rivals’.

Comparing Synairgen to Pfizer, Moderna, AZ etc is like claiming FC United of Manchester are rivals of Manchester United.

No small bio companies have had a product released to my knowledge.

I call bull**** on that - no way NDN has a girlfriend.

The way the price is going this morning we may well have a big seller.

A huge institution like Barclays is down 5% today, which is indicative of what’s happened across the majority of the market. I think it’s more to do with VP than RM but don’t let the truth get in the way of your nonsense.

Maybe Phoenix warehouse along the road in Portsmouth…..

Of course it’s taking longer than we hoped.

Is that the fault of the Synairgen team though? Should they have compromised the whole trial and future of the treatment by agreeing to do whatever the UK govt wanted? Should they have been forced to accept a tiny offer to have sold early to big pharma?

Maybe neither of these were even ever on the table.

But somehow, despite governments and big pharma pursuing their own agendas, a small company from Southampton found investors, attracted the attention of the US government and stand on the verge of huge success with a life saving treatment.

It’s a massive pain in the arse waiting but we’ve waited this long so will enjoy/endure the last remaining while before results are released.

Now, do us all a favour Andy and f*** off!